Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from MicroPort Scientific ( (HK:0853) ) is now available.
MicroPort Scientific has returned to profitability for the year ended 31 December 2025, posting net profit of US$38.4 million as revenue grew 6% and gross profit rose 10.5%. Non-GAAP operating profit swung from a loss to a small profit and operating cash flow turned positive, indicating a transition to a development phase driven by earnings and healthier cash generation.
The company’s “GloMatrix” commercialization platform delivered 78.8% revenue growth and reached breakeven, while overseas sales in surgical robots and structural heart disease surged, reinforcing platform synergies. Core cardiovascular intervention operations maintained an adjusted net profit margin above 20%, and strategic integration of structural heart and cardiac rhythm units, alongside robust innovation and regulatory wins, is strengthening its balance sheet and opening a new growth curve in heart failure care.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
More about MicroPort Scientific
MicroPort Scientific Corporation is a medical device company focused on cardiovascular intervention, structural heart disease, cardiac rhythm management and surgical robotics. The group targets both domestic and overseas markets, positioning itself as a total solution provider for coronary heart disease and an emerging global platform in high-value heart failure treatment technologies.
Average Trading Volume: 14,933,403
Technical Sentiment Signal: Sell
Current Market Cap: HK$18.85B
See more data about 0853 stock on TipRanks’ Stock Analysis page.